ALXO

Key highlights include data from ESMO Breast 2026 showing CD47 expression as a key predictive biomarker for EVO in HER2-positive patients; Dr. Sarah Hurwitz presenting ESMO breast data and views on avorbicept's potential; CMO Barb Quincy recapping EVO findings in two trials; update on phase 1 trial of EGFR-targeted ADC AOX 2004; continued progress of both EVO and AOX 2004 programs; completion of key hires and strong financing in Q1; Evorpercept phase two breast trial progressing well; AOX 2004 on track for initial safety readout in second half of 2026; goal to have both programs ready for registrational studies by end of next year.

Both EVO and AOX 2004 programs remain on track, with expected significant data readouts from these programs in the coming 12 to 18 months; Evorpercept phase two breast trial expected to read out 80 patients mid-next year; AOX 2004 on track for initial safety readout in second half of 2026; goal to have both programs ready for registrational studies by end of next year.

No specific financial performance data for product segments; focus is on progress of EVO and AOX 2004 programs. EVO showed positive data in HER2-positive cancers with CD47 as a predictive biomarker, and AOX 2004 is progressing in dose escalation for EGFR-expressing cancers.

No detailed discussion of specific risks and operational failures in the provided transcript

Q: For upcoming interim data readout in mid-2027 from Aspen breast study, what's compelling results in terms of ORR and DOR, and plan to put out NPFS data.

A: Expecting response rate assessment, duration of response may be preliminary, PFS possibly too immature; Q: How to use drug in clinical setting if approved and role of CD47 testing.

A: Aspen 09 study to validate data, potential companion diagnostic development with Ventana, cut point to be set; Q: Population in Aspen 09 and comparison to update today, cutoff for CD47, further development of ZANI combo.

A: Population similar, cutoff being optimized, targeted phase three study; Q: Companion diagnostic development and statistical powering.

A: Working on companion diagnostic, targeted approach allows tighter registrational study; Q: Consistency of CD47 high observation in Aspen 09, tissue adequacy and turnaround time.

A: Monitoring closely, no urgency for current study as it's single-arm; Q: Nuances of CD47 high cutoffs used.

A: Cutoffs may change, optimized with Aspen 09 data, cumulative total calculation in IHC